US-based biopharmaceutical services company Quintiles has announced a formal partnership with invivodata, which provides device-based eDiaries and other data collection tools to the pharmaceutical industry.
Under the agreement, invivodata becomes Quintiles’ preferred provider of electronic Patient Reported Outcomes (ePRO) solutions and services. According to the two companies, which have already collaborated informally on more than 20 joint studies, the relationship should “transform the way Patient Reported Outcomes are used in clinical research to speed drug development”.
The partnership will integrate invivodata’s PRO consulting, technology and service solutions with the full suite of Quintiles’ clinical services, reducing study complexity and cost “as redundant services are removed throughout all phases of drug development”, the companies said.
As Paula Brown Stafford, executive vice president, integrated clinical services for Quintiles, pointed out, regulators – and in particular the US Food and Drug Administration – have raised the pressure on drug developers to focus on the patient’s perspective of drug effects.
“While the patient perspective can be obtained in various ways, real-time PRO data are common measures of drug efficacy, and ePRO is an accurate and reliable way to capture these data,” she commented. “Quintiles has led the CRO market place in providing electronic data capture services and ePRO is a logical extension of that leadership for our customers.”
invivodata inc. is a privately held company with global headquarters in Pittsburgh, US and European headquarters in London, UK.
